Sumitomo Mitsui Trust Group Inc. Sells 2,664 Shares of Burning Rock Biotech Limited (NASDAQ:BNR)

Sumitomo Mitsui Trust Group Inc. lowered its holdings in shares of Burning Rock Biotech Limited (NASDAQ:BNR) by 4.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,639 shares of the company’s stock after selling 2,664 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Burning Rock Biotech were worth $349,000 at the end of the most recent reporting period.

Burning Rock Biotech Trading Up 13.0 %

Shares of BNR stock opened at $6.94 on Friday. Burning Rock Biotech Limited has a 12 month low of $2.62 and a 12 month high of $8.99. The stock has a market cap of $71.07 million, a P/E ratio of -2.31 and a beta of 0.55. The company has a 50 day simple moving average of $6.73 and a two-hundred day simple moving average of $5.30.

Burning Rock Biotech (NASDAQ:BNR) last issued its earnings results on Tuesday, December 3rd. The company reported ($0.50) earnings per share for the quarter. Burning Rock Biotech had a negative return on equity of 60.68% and a negative net margin of 83.50%.

Burning Rock Biotech Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.